VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan 4, 2023--

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Source: AbCellera Biologics Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230103005877/en/

CONTACT: Inquiries

Media: Jessica Yingling, Ph.D.;media@abcellera.com, +1(236)521-6774

Business Development: Murray McCutcheon, Ph.D.;bd@abcellera.com, +1(604)559-9005

Investor Relations: Josephine Hellschlienger, Ph.D.;ir@abcellera.com, +1(778)729-9116

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: AbCellera Biologics Inc.

Copyright Business Wire 2023.

PUB: 01/04/2023 04:05 PM/DISC: 01/04/2023 04:05 PM

http://www.businesswire.com/news/home/20230103005877/en